journal article·2019-05-13

Supramolecular Gels Derived from Simple Organic Salts of Flufenamic Acid: Design, Synthesis, Structures, and Plausible Biomedical Application

Rumana Parveen, Bandi Jayamma, Parthasarathi Dastidar

Publisher page

Abstract

Following supramolecular synthon rationale in the context of crystal engineering, a nonsteroidal-anti-inflammatory-drug (NSAID), namely flufenamic acid (FA) and its β-alanine monopeptide derivative (FM), were converted to a series of primary ammonium monocarboxylate (PAM) salts. Majority of the PAM salts (∼90%) showed gelation with various solvents including water and methyl salicylate (important solvents in topical gel formulation). Structure–property correlation studies based on single-crystal X-ray diffraction (SXRD) and powder X-ray diffraction (PXRD) data provided intriguing insights into the structure of the gel network. Furthermore, one of the gelator salts (S7) displayed anticancer activity on a highly aggressive human breast cancer cell line (MDA-MB-231) ,as revealed by MTT, PEG2, and cell migration assays.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Supramolecular Self-Assembly in Materials · Polydiacetylene-based materials and applications · Antimicrobial Peptides and Activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemical Sciences, Indian Association for the Cultivation of Science, 2A & 2B Raja S.C. Mullick Road, Kolkata 700032,West Bengal, India

Funding

Council for Scientific and Industrial Research · Department of Biotechnology , Ministry of Science and Technology

References (65)

Show source-provided references
1. 10.1039/b807346e10.1039/b807346e ↗
2. 10.1021/ja503363v10.1021/ja503363v ↗
3. 10.1039/C6CS00435K10.1039/C6CS00435K ↗
4. 10.1039/C2CS35284B10.1039/C2CS35284B ↗
5. 10.1039/b816192e10.1039/b816192e ↗
6. 10.1021/cr030204910.1021/cr0302049 ↗
7. 10.1021/ja036111q10.1021/ja036111q ↗
8. 10.1039/C7CS00804J10.1039/C7CS00804J ↗
9. 10.1021/jacs.8b0535910.1021/jacs.8b05359 ↗
10. 10.1002/anie.20110676710.1002/anie.201106767 ↗
11. 10.1039/c2cc17503g10.1039/c2cc17503g ↗
12. 10.1039/C4CC02504K10.1039/C4CC02504K ↗
13. 10.1080/09546630231758440310.1080/095466302317584403 ↗
14. 10.1021/ja000449s10.1021/ja000449s ↗
15. 10.1039/b9nj00764d10.1039/b9nj00764d ↗
16. 10.1021/ar900282h10.1021/ar900282h ↗
17. 10.1039/b507157g10.1039/b507157g ↗
18. 10.1016/j.biomaterials.2016.04.03910.1016/j.biomaterials.2016.04.039 ↗
19. 10.1021/cr000108x10.1021/cr000108x ↗
20. 10.1016/j.biomaterials.2007.07.02110.1016/j.biomaterials.2007.07.021 ↗
21. 10.1016/j.tetlet.2006.08.00210.1016/j.tetlet.2006.08.002 ↗
22. 10.1016/j.biomaterials.2008.09.04510.1016/j.biomaterials.2008.09.045 ↗
23. 10.1039/c1cc12570b10.1039/c1cc12570b ↗
24. 10.1002/adtp.20180006110.1002/adtp.201800061 ↗
25. 10.1002/1521-3773(20000703)39:13<2263::AID-ANIE2263>3.0.CO;2-V10.1002/1521-3773(20000703)39:13<2263::AID-ANIE2263>3.0.CO;2-V ↗
26. 10.1039/b511699f10.1039/b511699f ↗
27. 10.1038/nmat103410.1038/nmat1034 ↗
28. 10.1039/C5CS00136F10.1039/C5CS00136F ↗
29. 10.1146/annurev-matsci-070115-03155710.1146/annurev-matsci-070115-031557 ↗
30. 10.1039/978178801314710.1039/9781788013147 ↗
31. 10.1016/S0040-4020(00)00915-710.1016/S0040-4020(00)00915-7 ↗
32. 10.1021/ar050092310.1021/ar0500923 ↗
33. 10.1002/anie.19952311110.1002/anie.199523111 ↗
34. Desiraju G. R. · 201110.1142/8060 ↗
35. 10.1039/C5CE90184G10.1039/C5CE90184G ↗
36. Dastidar P. · 2015 · 10110.1007/978-3-662-45780-1_4 ↗
37. 10.1021/cm060501510.1021/cm0605015 ↗
38. 10.1002/chem.20040012210.1002/chem.200400122 ↗
39. 10.1039/C3CE42655F10.1039/C3CE42655F ↗
40. 10.1021/ol053000i10.1021/ol053000i ↗
41. 10.1039/b806410p10.1039/b806410p ↗
42. 10.1021/nn405724x10.1021/nn405724x ↗
43. 10.1021/acs.molpharmaceut.5b0093110.1021/acs.molpharmaceut.5b00931 ↗
44. 10.1021/acs.langmuir.6b0010010.1021/acs.langmuir.6b00100 ↗
45. 10.1021/acs.chemrev.5b0029910.1021/acs.chemrev.5b00299 ↗
46. 10.1073/pnas.173060910010.1073/pnas.1730609100 ↗
47. 10.1021/ja028539f10.1021/ja028539f ↗
48. 10.1039/B616563J10.1039/B616563J ↗
49. 10.1002/asia.20170004910.1002/asia.201700049 ↗
50. 10.1039/c3cc48513g10.1039/c3cc48513g ↗
51. 10.1007/1-4020-3689-2_910.1007/1-4020-3689-2_9 ↗
52. 10.1002/chem.20120098610.1002/chem.201200986 ↗
53. 10.1039/b713009k10.1039/b713009k ↗
54. 10.1371/journal.pone.003412210.1371/journal.pone.0034122 ↗
55. 10.1074/jbc.M10479420010.1074/jbc.M104794200 ↗
56. 10.1016/S0140-6736(00)04046-010.1016/S0140-6736(00)04046-0 ↗
57. Shacter E. · Oncology · 2002 · 16 · 217
58. 10.1186/bcr101910.1186/bcr1019 ↗
59. Ristimäki A. · Cancer Res. · 2002 · 62 · 632
60. 10.1093/carcin/bgi02210.1093/carcin/bgi022 ↗
61. 10.1016/j.prostaglandins.2011.08.00510.1016/j.prostaglandins.2011.08.005 ↗
62. 10.1016/S0014-4827(03)00269-610.1016/S0014-4827(03)00269-6 ↗
63. Srinivas S. · Anticancer Res. · 2009 · 29 · 3605
64. 10.1186/1471-2407-14-56710.1186/1471-2407-14-567 ↗
65. 10.1016/S0142-9612(01)00267-810.1016/S0142-9612(01)00267-8 ↗